Overview

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of Lu AA21004 in participants with major depressive disorder after completion of an 8-week double-blind treatment period in a preceding study (Lu AA21004/CCT-003; NCT01355081).
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Vortioxetine